Drug Type Small molecule drug |
Synonyms (2RS)-1-(4-ethylphenyl)-2-methyl-3-(1-piperidyl)propan-1-one, Eperisone, Eperisone hydrochloride (JP17) + [12] |
Target |
Mechanism VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (16 May 2014), |
Regulation- |
Molecular FormulaC17H26ClNO |
InChIKeyGTAXGNCCEYZRII-UHFFFAOYSA-N |
CAS Registry56839-43-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01671 | Eperisone Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Muscle Hypertonia | JP | 16 May 2014 | |
Spastic paralysis | JP | 16 May 2014 | |
Muscle Spasticity | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute low back pain | Phase 3 | - | 01 Mar 2014 | |
Intervertebral Disc Disease | Phase 3 | - | 01 Mar 2014 | |
Low Back Pain | Phase 3 | IN | 01 Apr 2006 | |
Spasm | Phase 3 | IN | 01 Apr 2006 |